PUNE - 411001

(Established in 1953)



Phone: 020 -26127301
Fax: 020 -26122669
Email :
Website :
Scope of Activities:

  • Situated at Pune in Maharashtra, the National Institute of Virology (NIV) conducts comprehensive research on Human Viruses of public health concern. In addition to emerging and re-emerging viruses such as KFD, Hepatitis E, HIV, Chandipura, Nipah, Chikungunya, Human metapneumo and H5N1/swine H1N1 other viruses Dengue, Hepatitis A-G, Japanese Encephalitis, West Nile, Measles, Rota, Human Influenza and Avian Influenza causing considerable morbidity and mortality are studied in depth.
  • A Microbial Containment Complex (MCC) having BSL 3+ bio-safety level facility for handling microorganisms of highly infectious nature has been established at Pashan, Pune. A Maximum Containment Laboratory (BSL4) is under advance stage of construction. These laboratories provide National facility for safe handling of highly hazardous pathogens.

Thrust Areas:

The following are the thrust areas of NIV

  • Thorough investigations of epidemics of viral /suspected viral and diseases of unknown etiology.
  • To serve as an apex national laboratory in providing quick and accurate diagnostic services whenever situation demands.
  • High quality applied and basic research on viruses of public health relevance including:
    • Precise assessment of prevalence of different viruses in different populations at different time points, identifying risk groups requiring interventions. Conducting similar studies in animals / mosquitoes and other insects.
    • Development of diagnostics, both serological and molecular.
    • Understanding of the genetic variation in viruses with time, location and clinical presentation
    • Development of vaccines employing different approaches
    • Pathogenesis of viral infections in animal models and humans
    • Partner to several national and international studies assessing efficacy of antivirals / vaccines, prevalence of viral infections and characterization of viruses.
    • To suggest preventive and control strategies for viral infections.
  • Timely supply of diagnostic kits to WHO, neighboring countries and network of laboratories identified by the government within India.
International Recognition:

  • NIV is a WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research.
  • NIV is a WHO National Influenza Center in India.
  • NIV is a WHO Influenza A H5 Reference laboratory for South East Asia.
  • The NIV Unit Bangalore is an accredited National Laboratory under National Polio Surveillance program.
Human Resource Development :

NIV conducts on a regular basis
  • M Sc Virology and PhD programs
  • Short-term projects to the students from different colleges and universities
  • Workshops for newly introduced and classical techniques.
Recognition for Doctorate/Masters by a University:

NIV is an affiliated institute of the Pune University. Both M Sc and Ph D degrees are awarded by this university.

Major Achievements:

The major achievements of NIV include: So far, the success stories of NIV, “from recognition to vaccine development” have been KFD, Hepatitis E and Chandipura.
  • In the earlier years, NIV’s contribution in defining role of different vectors in the spread of arboviruses and understanding of vector biology has been immense.
  • The first insect cell-line, C6/36, was developed at NIV and is used world wide for isolation of arboviruses.
  • Clinical trial of Measles vaccine produced by Serum Institute of India, Pune was jointly conducted by NIV and B J Medical College, Pune. This vaccine is used in majority of the countries in world.
  • Invaluable collection of over 2 million serum samples, a thousand strains of viruses, and 21 new-discovered viruses are in our repository.
  • Several new species of ticks, lice, flea, sand flies, mosquitoes and a new species of rodent has been described by the scientists of the institute.
  • For all hepatitis viruses age-stratified serosurveys conducted over 20 years documented changing epidemiology requiring re-thinking about vaccination policy
  • For several viruses, mutations over time were studied leading to calculation of evolutionary rates of the viruses.
  • Development of immunoassays for KFD, hepatitis A, B, E, JE, WN, DEN, CHP, Chikungunya, Rota and Measles viruses.
  • Development of molecular assays for diagnosis for almost all the viruses under investigation and real time PCR for the quantisation of HBV, HEV, HAV, HCV, CHP, Dengue and CHIK viruses.
  • HAV and JEV were transferred to an industry for the development of a killed vaccine
  • Recombinant protein-based vaccine for hepatitis E and a combination vaccine for hepatitis E and B was developed; preclinical trial in monkeys showed very promising results.
  • Documentation of Nipah virus as the etiology of an epidemic at Siliguri and Nadia with very high mortality.
  • The institute rose quickly to the emergency situations and provided diagnosis for SARS, H5N1, Chikungunya and swine H1N1 with the labs working 24-hours a day.
  • Avian Influenza virus – recombinant virus using reverse genetics developed with CDC – identified as prospective vaccine candidate by WHO
  • The institute produces thousands of ELISA kits for the diagnosis of JE, Dengue and Chikungunya and supplies to the national programs
  • Avian Influenza (H5N1) recombinant virus using reverse genetics developed with CDC was identified as prospective vaccine candidate by WHO
  • An animal model was developed for Chikungunya producing disease similar to humans
  • Patents obtained / filed:
    • Insect repellent device
    • Chimeric T helper B cell peptide
    • Use of IgY antibodies against rotavirus inf. in children and Poultry
    • Preparation & use of immune goat colostrum against rotavirus infection
    • ELISA for Rotavirus
    • Recombinant proteins of genotype-4 swine Hepatitis E virus.

  • Go Back